What Слезин Treats: Main Uses and Benefits

Слезин is commonly used for temporary symptomatic relief across therapeutic domains involving noticeable ocular discomfort and surface desiccation. The combination of Dextran 70 and Hypromellose is relevant in settings that involve symptoms that create noticeable physiological strain and the need to relieve dryness.

---

Key Applications and Symptom Management

This preparation is applied to help address symptoms related to physical discomfort, specifically the sensation of burning, stinging, and grittiness in the eyes. It is commonly used across conditions characterized by periods of heightened symptoms of tear film instability, such as mild to moderate Dry Eye Syndrome (DES). The therapeutic domain includes addressing symptoms associated with environmental exposure, situational strain from prolonged computer use, and providing supportive comfort in conditions presenting with chronic ocular surface needs.

This solution supports the patient during difficult episodes by easing distress associated with these symptoms. As a general supportive measure, it is relevant for easing symptoms that interfere with daily comfort and may help patients cope more steadily with symptom fluctuations.

Quick Facts: Symptom Relief Focus
This solution is commonly used to help with acute or recurrent symptomatic episodes involving grittiness, burning, and stinging, contributing to improved day-to-day comfort and assisting with maintaining functional stability.

Regulatory References

1. DailyMed (NIH) label information

The official regulatory documents define the eligible population for Слезин (Dextran 70 / Hypromellose ophthalmic solution) with few restrictions, consistent with its classification as an inert, non-systemic ophthalmic lubricant.

Who Must Not Use Слезин (Contraindication)

The single absolute prohibition documented across official labeling is a known hypersensitivity to the active substances (Dextran 70, Hypromellose) or to any of the excipients in the formulation. Patients with a documented allergy to any ingredient must not use this medicine.

General Eligibility

Use of this medicine is established and permitted for all major age groups: adults, children, and the elderly. Regulatory bodies state that use in the geriatric population is not expected to cause different side effects or problems than in adults.

Special Populations and Restrictions

Due to the inert nature and negligible systemic absorption of the active components, use is permitted for pregnant and breastfeeding women. No specific eligibility restrictions are documented based on renal or hepatic impairment or other systemic comorbidities.

A key restriction applies to administration: the medicine must not be administered while contact lenses are being worn. Lenses must be removed prior to application, and patients should wait at least fifteen minutes before reinsertion.

Interactions with other medicines and products

Regulatory labeling for Слезин (Dextran 70 and Hypromellose ophthalmic solution) defines its interaction profile based on its physical, topical action and negligible systemic absorption. The active components are high molecular weight polymers that are not expected to be absorbed systemically; consequently, clinically relevant systemic drug interactions are not documented in official sources.

---

Documented Interaction Patterns

Interaction Scope	Official Regulatory Statement
Systemic Pharmacokinetic Interactions	None documented. No CYP-mediated or transporter interactions are noted in regulatory labels.
Drug–Substance Interactions	None documented. No interactions with food, alcohol, or herbal products are specified.
Primary Pharmacodynamic Interaction	Local Physical Interference with other preparations.

---

Administration-Timing Restriction

The primary documented constraint involves simultaneous use with other topical ophthalmic medicinal products. This constitutes an administration-timing interaction intended to prevent the physical disruption or washing out of another medicine, which could reduce its local efficacy.

• If using any other eye drops or eye ointments, the administration of each product must be separated by a minimum of 5 minutes.
• The specific procedural constraint requires that eye ointments should always be administered last among the combination of topical preparations.

Core Mechanism: Alpha-2 Adrenergic Agonism

Слезин (Xylazine) acts as an agonist at presynaptic alpha-2 (alpha2) adrenergic receptors located in the Central Nervous System (CNS) and peripheral tissues. Receptor activation initiates a negative feedback loop that reduces the presynaptic release of the excitatory neurotransmitters norepinephrine and dopamine into the synaptic cleft. This molecular event defines the drug's functional class.

---

Mechanistic Cascade: Central and Systemic Effects

The resulting decrease in noradrenergic activity leads to widespread CNS depression and reduced arousal. This central effect produces the physiological consequences of sedation and skeletal muscle relaxation.

At the systemic level, the mechanism interferes with nociceptive pathways in the spinal cord, thereby inhibiting pain signal transmission. Furthermore, the modulation of central sympathetic outflow alters autonomic regulation, causing predictable cardiovascular adjustments, specifically bradycardia (slowed heart rate) and hypotension (lowered blood pressure).

The usage protocol for Слезин (Dextran 70 and Hypromellose Ophthalmic Solution) is established for proper topical administration and is primarily based on the presence of symptoms, outlining a standardized approach to its self-administration.

Administration Protocol

Instruction	Specification
Route of administration	Topical Ocular Instillation
Dosing schedule	Instill 1 or 2 drops in the affected eye(s)
Frequency pattern	Applied as needed (ad-hoc) for discomfort
Preparation requirements	The solution is sterile and ready for use; no dilution is required.
Age-group rules	No specific dose adjustments are provided for pediatric patients, older adults, or those with organ impairment.
Special handling	Strict instruction to avoid contamination of the bottle tip (do not touch the tip to any surface).

Resulting Procedural Structure

The use of Слезин is characterized by an on-demand application method. The solution is exclusively administered to the conjunctival sac, with the frequency determined by the recurrence of ocular dryness.

Standardized step sequence:

• Instill the solution by applying 1 or 2 drops into the affected eye(s).
• Repeat the instillation as needed based on the return of discomfort.
• Maintain sterility by ensuring the dispenser tip does not contact the eye, eyelid, or any other surface.

This protocol establishes the medication as a supportive, intermittent measure. The entire administration process is defined by the need for symptomatic relief, with the user managing the frequency within the confines of the established dose range. The instructions require the user to adhere to the non-contact rule, which is essential for maintaining the product's integrity during self-administration.

Research evidence / Overview of Studies for Слезин

---

Research Evidence for Temporary Symptom Relief of Ocular Dryness

The clinical research on the dual-polymer ophthalmic solution (Dextran 70 and Hypromellose) was explored in Randomized Controlled Trials (RCTs) and Systematic Reviews examining how symptoms change over time for individuals with mild to moderate dry eye syndrome. The evidence base contributes to understanding this preparation within the broader class of artificial tears. In these studies, researchers monitored both patient-reported outcomes describing perceived discomfort, such as stinging and grittiness, and objective clinical signs outcomes related to physiological strain, like the stability of the tear film.

Studies conducted during periods of increased symptom activity monitored how symptoms evolved in the observed populations over short intervals. Findings describe patterns observed in the studies related to outcomes related to physical discomfort over the short study intervals. Comparative studies observed that this formulation was associated with patterns in measured outcomes relevant to comparative research alongside other active comparator lubricant drops.

---

Research Evidence for Supportive Use in Glaucoma Patients

This solution was studied for specific clinical contexts, such as in patients who experience ocular surface issues due to the chronic use of anti-glaucoma medication. This research involved Randomized, Double-Blind Studies to compare the solution against other lubricant types in this specific adult population. Studies monitored outcomes related to physical discomfort and daily functioning, such as changes in the Ocular Surface Disease Index (OSDI) scores. Findings describe patterns observed in the studies, related to changes in both subjective symptoms and objective clinical signs over the intermediate study periods.

---

Focus on Study Duration and Long-Term Follow-up

The vast majority of research focusing on this specific dual-polymer formulation explored responses over defined time intervals that are relatively short, typically 2 to 4 weeks. Research provides context but not individual predictions beyond this immediate follow-up duration. Long-term effects are not fully established, as there is limited information for long-term outcomes regarding the sustained effects or durability of the response over several months or years.

---

Understanding Research Gaps and Uncertainty

Research exploring the Dextran 70/Hypromellose formulation contributes to the broader evidence landscape of ocular lubricants, but evidence quality varies across studies, leading to some uncertainty. One key limitation is that comparative evidence is lacking across all current artificial tear products. Additionally, since the follow-up durations were limited, there is a gap in understanding how the preparation influences the overall management of chronic ocular surface needs over time. These research limitations mean that individual predictions cannot be drawn from the evidence.

Key Studies & References

1. Comparison of the clinical efficacy of preserved and preservative-free hydroxypropyl methylcellulose-dextran-containing eyedrops (RCT comparing Dextran 70/Hypromellose formulations)
2. GENTEAL TEARS MODERATE PRESERVATIVE FREE- dextran 70, hypromellose 2910 solution/ drops (Example of Regulatory/Label Information for the dual-polymer formulation)

Common questions about Слезин (FAQ)

Q: Does this medication make you sleepy or affect your ability to drive?

Official regulatory documents indicate that this medication may cause dizziness and sleepiness (somnolence). These known effects could potentially impair your judgment and reaction time. Therefore, it is recommended that patients understand how the medication affects them before driving or operating complex machinery.

Q: Is it safe to take this medication long-term?

Official product information notes that long-term use is associated with risks, including the potential for developing dependence, abuse, and misuse. Patients should also be monitored for withdrawal symptoms if the medication is stopped, as well as for potential side effects such as weight gain and edema (swelling).

Q: Can children 2 years old use this medication?

Regulatory information specifies that this medication is not approved for nerve pain indications in children under 18 years of age. However, the label does include approval for use as a supportive treatment for partial-onset seizures in patients aged 1 month and older.

How to Store and Dispose of Слезин (Dextran 70 / Hypromellose Ophthalmic Solution)

---

Official Regulatory Requirements

Category	Requirement
Storage Temperature	Store below 25°C (Controlled Room Temperature).
Handling	Do not refrigerate or freeze. Keep the container tightly closed.
In-Use Stability	Discard the remaining product four weeks after first opening.
Contamination Rule	To avoid contamination, do not allow the dropper tip to touch any surface.
Child Safety	Keep out of the sight and reach of children.
Disposal	Do not throw away via wastewater or household waste. Ask a pharmacist how to dispose of unused medicine.

---

Official documents strictly require storing this ophthalmic solution below 25°C while prohibiting refrigeration. The product must be protected from contamination by keeping the bottle tightly closed and must be discarded within four weeks of opening. For public safety, the medicine must always be kept out of the reach of children and disposed of through appropriate pharmaceutical waste channels, not household trash or sinks.